![](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1635175749/Durvalumab_0.jpg/Durvalumab_0.jpg?VersionId=ACfHjP.gbDxGFoOp5Nv7yKn.JkKn0Gcn)
Ahead of adcomm, FDA pokes holes in AZ's perioperative lung cancer filing for Imfinzi
Interim results from a phase 3 trial of AstraZeneca’s Imfinzi as a treatment before and after surgery in resectable non-small cell lung cancer (NSCLC) were head-scratching as they failed to answer two key questions. Do both treatment settings optimize the …